

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Johannes Coy Examiner: Peter J. REDDIG, Ph.D.

Application No.: 10/539,233 Group: 1642

Date filed: June 16, 2005 Confirmation No: 7127

For: **COMPOUNDS AND METHODS FOR DETECTION OF CARCINOMAS
AND THEIR PRECURSOR LESIONS**

INTERVIEW SUMMARY

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir/Madam:

This paper constitutes the Applicant's Interview Summary required under 37 C.F.R. §1.133.

The interview occurred telephonically on May 8, 2007. Participants were Examiner Peter J. Reddig, Examiner Susan Ungar, and attorney Blair Lanier.

Proposed amendments to pending claims 27-43 were discussed. Additionally, the forty-nine group restriction requirement was discussed. Applicant takes no position on the appropriateness of forty-nine group restriction requirement, but Applicant will select a group due to procedural requirements. Thereafter, Applicant will submit amendments to the claims. Examiner Ungar indicates that upon filing said amendments, the forty-nine group restriction may be withdrawn, and a new restriction requirement may be issued.

No agreement was reached.

Applicant is grateful for the opportunity to speak with the Examiners regarding this matter. Applicant requests this Summary be entered into the record in compliance with 37 C.F.R. § 1.133. The Examiners are encouraged to contact the undersigned telephonically should they have any further concerns regarding this Application.

Johannes Coy
Application No. 10/539,233
Interview Summary
Page 2 of 2

Respectfully submitted,
AKERMAN SENTERFITT

Date: June 18, 2007

Docket No. 4007-009

Blair R. Lanier
Blair R. Lanier
Registration No. 56,910
AKERMAN SENTERFITT
P.O. Box 3188
West Palm Beach, FL 33402-3188
Tel: 561-653-5000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Johannes Coy Examiner: Peter J. REDDIG, Ph.D.

Application No.: 10/539,233 Group: 1642

Date filed: June 16, 2005 Confirmation No: 7127

For: **COMPOUNDS AND METHODS FOR DETECTION OF CARCINOMAS AND THEIR PRECURSOR LESIONS**

INTERVIEW SUMMARY

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir/Madam:

This paper constitutes the Applicant's Interview Summary required under 37 C.F.R. §1.133.

The interview occurred telephonically on June 1, 2007. Participants were Examiner Peter J. Reddig, Examiner Susan Ungar, and attorney Blair Lanier.

Amendments to the claims, as filed on May 18, 2007 were discussed in relation to the forty-nine group restriction requirement issued March 9, 2007. Agreement was reached that in view of the claim amendments submitted May 18, 2007, the March 9, 2007 restriction requirement would be withdrawn and a second restriction requirement issued.

It was agreed that the second restriction requirement shall be issued containing the following groups:

Group 1 Claims 27-37 A method indicating whether a test sample is affected by a **carcinoma** of which the control sample is unaffected by detecting levels of **DNase-X polypeptide**.

Group 2 Claims 27-37 A method indicating whether a test sample is affected by a **precursor lesion** of which the control sample is unaffected by detecting levels of **DNase-X polypeptide**.

Group 3 Claims 27-37 A method indicating whether a test sample is affected by a **carcinoma** of which the control sample is unaffected by detecting levels of **DNase-X nucleic acid**.

Johannes Coy
Application No. 10/539,233
Interview Summary
Page 2 of 2

Group 4 Claims 27-37 A method indicating whether a test sample is affected by a **precursor lesion** of which the control sample is unaffected by detecting levels of **DNase-X nucleic acid**.

Group 5 Claim 39 A method of identifying and obtaining drug candidates.

Group 6 Claims 38 and 43 drawn to a probe binding to DNase-X **polypeptide** and a kit for **detecting** cancer.

Group 7 Claims 38 and 43 drawn to a probe binding to DNase-X **nucleic acid** and a kit for **detecting** cancer.

Group 8 Claims 40-42 drawn to a kit/pharmaceutical composition useful for the **treatment** of cancer and their precursor lesions.

In response to the second restriction requirement, it was recognized that Applicant elects the following group:

Group 6 Claims 38 and 43 drawn to a probe binding to DNase-X **polypeptide** and a kit for **detecting** cancer.

Applicant is grateful for the opportunity to speak with the Examiners regarding this matter. Applicant requests this Summary be entered into the record in compliance with 37 C.F.R. § 1.133. The Examiners are encouraged to contact the undersigned telephonically should they have any further concerns regarding this Application.

Respectfully submitted,
AKERMAN SENTERFITT

Date: June 18, 2007

Docket No. 4007-009

Blair R. Lanier
Blair R. Lanier
Registration No. 56,910
AKERMAN SENTERFITT
P.O. Box 3188
West Palm Beach, FL 33402-3188
Tel: 561-653-5000